View in EDS HTML Full Text PDF Full Text

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.

Saved in:
Bibliographic Details
Title: Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Authors: Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Beeram M; South Texas Accelerated Research Therapeutics, San Antonio, TX, United States., Beck JT; Department of Medical Oncology and Hematology, Highlands Oncology, Springdale, AR, United States., Conlin A; Providence Cancer Center, Portland, OR, United States., Dees EC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Puhalla SL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States., Rexer BN; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States., Burris HA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States., Jhaveri K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.; Department of Medicine, Weil Cornell Medical College, New York, NY, United States., Helsten T; Moores Cancer Center, University of California San Diego, San Diego, CA, United States., Becerra C; Texas Oncology, Dallas, TX, United States., Kalinsky K; Department of Medicine, Columbia University, New York, NY, United States.; Department of Hematology/Oncology, Emory University Winship Cancer Institute, Atlanta, GA, United States., Moore KN; Stevenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.; Sarah Cannon Research Institute, Nashville, TN, United States., Manuel AM; Eli Lilly and Company, Indianapolis, IN, United States., Lithio A; Eli Lilly and Company, Indianapolis, IN, United States., Price GL; Eli Lilly and Company, Indianapolis, IN, United States., Chapman SC; Eli Lilly and Company, Indianapolis, IN, United States., Litchfield LM; Eli Lilly and Company, Indianapolis, IN, United States., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.
Source: Frontiers in oncology [Front Oncol] 2022 Feb 10; Vol. 11, pp. 810023. Date of Electronic Publication: 2022 Feb 10 (Print Publication: 2021).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35223458
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.<br /><searchLink fieldCode="AU" term="%22Beeram+M%22">Beeram M</searchLink>; South Texas Accelerated Research Therapeutics, San Antonio, TX, United States.<br /><searchLink fieldCode="AU" term="%22Beck+JT%22">Beck JT</searchLink>; Department of Medical Oncology and Hematology, Highlands Oncology, Springdale, AR, United States.<br /><searchLink fieldCode="AU" term="%22Conlin+A%22">Conlin A</searchLink>; Providence Cancer Center, Portland, OR, United States.<br /><searchLink fieldCode="AU" term="%22Dees+EC%22">Dees EC</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.<br /><searchLink fieldCode="AU" term="%22Puhalla+SL%22">Puhalla SL</searchLink>; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Rexer+BN%22">Rexer BN</searchLink>; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.<br /><searchLink fieldCode="AU" term="%22Burris+HA%22">Burris HA</searchLink>; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States.<br /><searchLink fieldCode="AU" term="%22Jhaveri+K%22">Jhaveri K</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.; Department of Medicine, Weil Cornell Medical College, New York, NY, United States.<br /><searchLink fieldCode="AU" term="%22Helsten+T%22">Helsten T</searchLink>; Moores Cancer Center, University of California San Diego, San Diego, CA, United States.<br /><searchLink fieldCode="AU" term="%22Becerra+C%22">Becerra C</searchLink>; Texas Oncology, Dallas, TX, United States.<br /><searchLink fieldCode="AU" term="%22Kalinsky+K%22">Kalinsky K</searchLink>; Department of Medicine, Columbia University, New York, NY, United States.; Department of Hematology/Oncology, Emory University Winship Cancer Institute, Atlanta, GA, United States.<br /><searchLink fieldCode="AU" term="%22Moore+KN%22">Moore KN</searchLink>; Stevenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.; Sarah Cannon Research Institute, Nashville, TN, United States.<br /><searchLink fieldCode="AU" term="%22Manuel+AM%22">Manuel AM</searchLink>; Eli Lilly and Company, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Lithio+A%22">Lithio A</searchLink>; Eli Lilly and Company, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Price+GL%22">Price GL</searchLink>; Eli Lilly and Company, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Chapman+SC%22">Chapman SC</searchLink>; Eli Lilly and Company, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Litchfield+LM%22">Litchfield LM</searchLink>; Eli Lilly and Company, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Goetz+MP%22">Goetz MP</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN, United States.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2022 Feb 10; Vol. 11, pp. 810023. <i>Date of Electronic Publication: </i>2022 Feb 10 (<i>Print Publication: </i>2021).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35223458
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2021.810023
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 810023
    Titles:
      – TitleFull: Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tolaney SM
      – PersonEntity:
          Name:
            NameFull: Beeram M
      – PersonEntity:
          Name:
            NameFull: Beck JT
      – PersonEntity:
          Name:
            NameFull: Conlin A
      – PersonEntity:
          Name:
            NameFull: Dees EC
      – PersonEntity:
          Name:
            NameFull: Puhalla SL
      – PersonEntity:
          Name:
            NameFull: Rexer BN
      – PersonEntity:
          Name:
            NameFull: Burris HA
      – PersonEntity:
          Name:
            NameFull: Jhaveri K
      – PersonEntity:
          Name:
            NameFull: Helsten T
      – PersonEntity:
          Name:
            NameFull: Becerra C
      – PersonEntity:
          Name:
            NameFull: Kalinsky K
      – PersonEntity:
          Name:
            NameFull: Moore KN
      – PersonEntity:
          Name:
            NameFull: Manuel AM
      – PersonEntity:
          Name:
            NameFull: Lithio A
      – PersonEntity:
          Name:
            NameFull: Price GL
      – PersonEntity:
          Name:
            NameFull: Chapman SC
      – PersonEntity:
          Name:
            NameFull: Litchfield LM
      – PersonEntity:
          Name:
            NameFull: Goetz MP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 02
              Text: 2022 Feb 10
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 11
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1